Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024
Paris, France – March 6, 2024
Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases based on its unique Mimicry platform, today announced that data on its novel OncoMimics™ approach to cancer immunotherapy will be presented in a poster at the upcoming American Association of Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California. The poster will be presented by Dr. Vincent Panneton, Postdoctoral Associate in Pharmacology at the Ludwig Collaborative Laboratory led by Dr. Taha Merghoub and Dr. Jedd Wolchok at Weill Cornell Medicine.
Research conducted by Weill Cornell Medicine and Enterome shows that in animal models microbiome-derived antigenic peptides (OncoMimics™ peptides), selected for their mimicry of tumor-associated antigens (TAAs) and neoantigens, effectively trigger cytotoxic T-cell immune responses. Through tumor challenge experiments with OncoMimics™ and checkpoint inhibitors, the researchers have also identified key parameters that enable them to predict the cross-reactive potential of OncoMimics™ peptides and facilitate the development of novel cancer immunotherapies.
“We are pleased to announce the presentation of these promising preclinical data which provide novel insights into the design of OncoMimics™ peptides for both neoantigens and tumor-associated antigens. These results serve as an early validation of our approach to novel cancer immunotherapies,” said Laurent Chêne, Head of Drug Discovery at Enterome.
Poster presentation details – Abstract 4090
Title: “Gut Microbiota Mimics as a Source of Cross-Reactive Tumor Rejection Antigens”
Presenting Author: Vincent Panneton, Ph.D., Postdoctoral Associate Weill Cornell Medicine
Session date: Tuesday Apr 9th, 2024 9 AM – 12:30
Location : Poster section 5, board number 1
The abstract will be published in an online supplement to Cancer Research, the official journal of the American Association for Cancer Research, on March 22nd, and the poster will be available on Enterome’s website after the AACR Meeting.
About OncoMimics™
OncoMimics™ immunotherapies are designed to activate pre-existing effector memory T cells that target bacterial (non-self) peptides, which are strongly cross-reactive against selected Tumor-Associated Antigens (TAAs), or B cell markers expressed on tumoral cells, resulting in a rapid, targeted cytotoxic response against cancer.
Contacts
| ENTEROME | MEDIA RELATIONS |
| Guillaume Bayre
Head of External Communications Tel: +33 (0)1 76 21 58 15 |
LifeSci Advisors LLC
Ashley R. Robinson (US) +1 617 430 7577 Sandya von der Weid (Europe) +41 78 680 05 38 |
Download the press release (.pdf format)
